Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Magainin Pharm (MAGN) -- Ignore unavailable to you. Want to Upgrade?

To: kech who wrote (168)	3/17/1999 11:59:00 AM
From: Shlepper	Respond to of 233

Tom, If you listened to the BLSI CEO being interviewed, he made a big point about mentioning about how all of the big pharmas were lining up to team with him. Imagine how great the prospects are for Magainin with squalamine for a positive arrangement. Shlepp

To: kech who wrote (168)	4/5/1999 4:14:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 233

A fellow pointed out MAGN to me on another thread recently, and I started to get interested again...I had given it up for dead after the FDA disapproved that froggie foot cream, but I wonder if anybody here can comment on the fact that Squalamine seems to work in combination therapy. What do these numbers tell you? The triple combination therapy produced a TGI of 95.7% (3/10 animals) and a tumor shrinkage of 54.8% (4/10 animals) compared to the TGI of 55.9% and no tumor shrinkage without the addition of squalamine. I would just link over to the aacr website, but you have to use a password etc... Thanks ahead of time...I wouldn't normally be too interested, but it looks as though the stock has bottomed out...so maybe this is not a bad entry point.